Daniel ODay
Biotech

CEO O’Day tells Fierce how Gilead reached ‘critical mass’

After a run of dealmaking, Gilead CEO Daniel O'Day told Fierce that any future M&A activity will only be done to complement the existing strategy.
Darren Incorvaia Sep 16, 2026 8:00am
Moving NAMs from Progress to Practice Building the Foundation for Broader Adoption

Moving NAMs from Progress to Practice

Brought to you by Battelle
Darts failing to hit bullseye

Novartis ends ALS program after phase 2 flop, adding to R&D woes

Sep 16, 2026 10:28am
The signal that changes everything understanding MRD in oncology drug development

The signal that changes everything: understanding MRD in oncology drug development

Brought to you by Natera
Novartis

Novartis pays Sironax $125M to acquire brain delivery platform

Sep 16, 2026 8:32am
Hand passing wad of bills to other hand

Sling reels in $123M to fund oral Tepezza rival through ph. 3

Sep 16, 2026 7:00am
More News

FDA launches pilot program to speed up sluggish phase 1 trials

Sep 15, 2026 2:09pm

Fierce Biotech Layoff Tracker 2026: Sionna, Merck & more

Sep 15, 2026 10:00am

Connect not dismayed by Dupixent rival's ph. 2 asthma failure

Sep 15, 2026 9:55am

Fierce Biotech Fundraising Tracker '26: Sling, Circle & more

Sep 15, 2026 9:45am